Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-10-2019 | Letter to the Editor

Is (S)-norketamine an alternative antidepressant for esketamine?

Authors: Kenji Hashimoto, Chun Yang

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2019

Excerpt

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has been hailed as the most important advance in the treatment of depression for the past 50 years. The rapid and sustained antidepressant effects of (R,S)-ketamine have spurred a great deal of research interest, with growing off-label use for the treatment of depression, although the concerns about the safety of repeated (R,S)-ketamine infusions persist [1]. …

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74:399–405CrossRefPubMed

Hashimoto K (2016) R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46:2449–2451CrossRefPubMed

Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632CrossRefPubMedPubMedCentral

Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D_2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267:173–176CrossRefPubMed

Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80:424–431CrossRefPubMed

Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2018) Efficacy and safety on intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75:139–148CrossRefPubMed

Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620–630.CrossRefPubMed

Psychiatric News (2018) J&J presents mixed findings for esketamine nasal spray at APA Annual Meeting. https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2018.pp5a2

Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: a systemic review. Lancet Psychiatry 5:65–78CrossRefPubMed

10.

Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, Ren Q, Zhang JC, Ma M, Toki H, Yamaguchi J, Chaki S, Shirayama Y, Nakazawa K, Manabe T, Hashimoto K (2018) AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. https://doi.org/10.1016/j.biopsych.2018.05.007 CrossRefPubMed

Title: Is (S)-norketamine an alternative antidepressant for esketamine?
Authors: Kenji Hashimoto
Chun Yang
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2019
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0922-2

At a glance: The STEP trials

Springer Medicine

Is (S)-norketamine an alternative antidepressant for esketamine?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2019

Cerebral blood flow responses during prosaccade and antisaccade preparation in major depression

Combined cognitive, psychomotor and electrophysiological biomarkers in major depressive disorder

Amygdala response and functional connectivity during cognitive emotion regulation of aversive image sequences

Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort

Prevalence of seasonal depression in a prospective cohort study

Bipolar disorder in the balance